View in EDS PDF Full Text

Ceftolozane-tazobactam in nosocomial pneumonia.

Saved in:
Bibliographic Details
Title: Ceftolozane-tazobactam in nosocomial pneumonia.
Authors: Javier Candel, Francisco1 franciscojavier.candel@salud.madrid.org, González del Castillo, Juan2, Julián Jiménez, Agustín3, Matesanz, Mayra4
Source: Revista Española de Quimioterapia. 2022 Supplement, Vol. 35, p35-39. 5p.
Subjects: PNEUMONIA, CEFTAROLINE, ANTI-infective agents, PSEUDOMONAS aeruginosa, LACTAMS
Abstract: Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the treatment of Pseudomonas aeruginosa infection. The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients. It has been shown to be non-inferior to meropenem in the treatment of nosocomial infection in the ASPECT-NP study but superior in post-hoc studies in the subgroup of patients with ventilator-associated pneumonia, without the emergence of resistance during treatment. It is FDA approved at a dose of 3 g every 8 hours in the treatment of nosocomial pneumonia (HABP/VABP) in adults. [ABSTRACT FROM AUTHOR]
Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 156575909
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Ceftolozane-tazobactam in nosocomial pneumonia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Javier+Candel%2C+Francisco%22">Javier Candel, Francisco</searchLink><relatesTo>1</relatesTo><i> franciscojavier.candel@salud.madrid.org</i><br /><searchLink fieldCode="AR" term="%22González+del+Castillo%2C+Juan%22">González del Castillo, Juan</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Julián+Jiménez%2C+Agustín%22">Julián Jiménez, Agustín</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Matesanz%2C+Mayra%22">Matesanz, Mayra</searchLink><relatesTo>4</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Española+de+Quimioterapia%22">Revista Española de Quimioterapia</searchLink>. 2022 Supplement, Vol. 35, p35-39. 5p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22PNEUMONIA%22">PNEUMONIA</searchLink><br /><searchLink fieldCode="DE" term="%22CEFTAROLINE%22">CEFTAROLINE</searchLink><br /><searchLink fieldCode="DE" term="%22ANTI-infective+agents%22">ANTI-infective agents</searchLink><br /><searchLink fieldCode="DE" term="%22PSEUDOMONAS+aeruginosa%22">PSEUDOMONAS aeruginosa</searchLink><br /><searchLink fieldCode="DE" term="%22LACTAMS%22">LACTAMS</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the treatment of Pseudomonas aeruginosa infection. The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients. It has been shown to be non-inferior to meropenem in the treatment of nosocomial infection in the ASPECT-NP study but superior in post-hoc studies in the subgroup of patients with ventilator-associated pneumonia, without the emergence of resistance during treatment. It is FDA approved at a dose of 3 g every 8 hours in the treatment of nosocomial pneumonia (HABP/VABP) in adults. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=156575909
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.37201/req/s01.08.2022
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 5
        StartPage: 35
    Subjects:
      – SubjectFull: PNEUMONIA
        Type: general
      – SubjectFull: CEFTAROLINE
        Type: general
      – SubjectFull: ANTI-infective agents
        Type: general
      – SubjectFull: PSEUDOMONAS aeruginosa
        Type: general
      – SubjectFull: LACTAMS
        Type: general
    Titles:
      – TitleFull: Ceftolozane-tazobactam in nosocomial pneumonia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Javier Candel, Francisco
      – PersonEntity:
          Name:
            NameFull: González del Castillo, Juan
      – PersonEntity:
          Name:
            NameFull: Julián Jiménez, Agustín
      – PersonEntity:
          Name:
            NameFull: Matesanz, Mayra
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 04
              Text: 2022 Supplement
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 02143429
          Numbering:
            – Type: volume
              Value: 35
          Titles:
            – TitleFull: Revista Española de Quimioterapia
              Type: main
ResultId 1